Literature DB >> 30392546

State-of-the-Art Diagnosis and Treatment of Hypertension in Pregnancy.

Laura A Magee1, Peter von Dadelszen2.   

Abstract

Hypertension complicates up to 10% of pregnancies worldwide. Pregnancy hypertension is defined as systolic blood pressure (BP) equal to or greater than 140 mm Hg or diastolic BP equal to or greater than 90 mm Hg, usually on the basis of measurements in office/clinic settings and using various BP devices. Hypertensive disorders of pregnancy are classified into (1) chronic hypertension diagnosed before pregnancy or before 20 weeks' gestation, (2) gestational hypertension diagnosed at equal to or greater than 20 weeks, or (3) preeclampsia, defined restrictively as gestational hypertension with proteinuria or broadly as gestational hypertension with proteinuria or an end-organ manifestation consistent with preeclampsia. Absolute BP values equal to or greater than 140/90 mm Hg are associated with increased maternal and perinatal risks, particularly with preeclampsia. This review focuses on antihypertensive therapy of hypertensive disorders of pregnancy as a specific management strategy. Underpinning this therapy is the need for accurate measurement of BP, agreed-upon classification of pregnancy hypertension, agreed-upon BP thresholds for enhanced surveillance and antihypertensive treatment, and collaborative teamwork in management. Challenges relate to the methodology of studies on which care is based, as well as aspects of the care itself, particularly the unregulated use of home BP monitoring. Pitfalls include the unsubstantiated belief that nifedipine and magnesium sulfate cannot be used together and the perception that severe hypertension and nonsevere hypertension are separate entities rather than lying along a spectrum of BP values. The following must be addressed by future research: guidance for nuanced care as women transition between severe and nonsevere hypertension, personalized antihypertensive therapy, and incorporation of women's values into research priorities and clinical practice when antihypertensive care is chosen.
Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30392546     DOI: 10.1016/j.mayocp.2018.04.033

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

1.  Preeclamptic Women Have Decreased Circulating IL-10 (Interleukin-10) Values at the Time of Preeclampsia Diagnosis: Systematic Review and Meta-Analysis.

Authors:  Meryl C Nath; Hajrunisa Cubro; Daniel J McCormick; Natasa M Milic; Vesna D Garovic
Journal:  Hypertension       Date:  2020-10-26       Impact factor: 10.190

2.  NFKB1-mediated downregulation of microRNA-106a promotes oxidative stress injury and insulin resistance in mice with gestational hypertension.

Authors:  Yunxia Guo; Zhaofang Liu; Ming Wang
Journal:  Cytotechnology       Date:  2021-01-04       Impact factor: 2.058

Review 3.  A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics).

Authors:  Liona C Poon; Laura A Magee; Stefan Verlohren; Andrew Shennan; Peter von Dadelszen; Eyal Sheiner; Eran Hadar; Gerard Visser; Fabricio Da Silva Costa; Anil Kapur; Fionnuala McAuliffe; Amala Nazareth; Muna Tahlak; Anne B Kihara; Hema Divakar; H David McIntyre; Vincenzo Berghella; Huixia Yang; Roberto Romero; Kypros H Nicolaides; Nir Melamed; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-07       Impact factor: 4.447

4.  Second trimester maternal serum D-dimer combined with alpha-fetoprotein and free β-subunit of human chorionic gonadotropin predict hypertensive disorders of pregnancy: a systematic review and retrospective case-control study.

Authors:  Yiming Chen; Yijie Chen; Xue Wang; Xuelian Chu; Wenwen Ning; Linyuan Gu; Liyao Li; Zhen Xie; Caihe Wen
Journal:  J Transl Med       Date:  2021-03-02       Impact factor: 5.531

Review 5.  Pregnancy-Related Extracellular Vesicles Revisited.

Authors:  Carmen Elena Condrat; Valentin Nicolae Varlas; Florentina Duică; Panagiotis Antoniadis; Cezara Alina Danila; Dragos Cretoiu; Nicolae Suciu; Sanda Maria Crețoiu; Silviu Cristian Voinea
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

6.  Evaluation of Cardiac Function of Pregnant Women with High Blood Pressure during Gestation Period and Coupling of Hearts with Peripheral Vessels by Ultrasonic Cardiogram under Artificial Intelligence Algorithm.

Authors:  Xia Zhang; Xi Liang; Wen Cao
Journal:  Comput Math Methods Med       Date:  2022-01-27       Impact factor: 2.238

7.  Predicting Hypertensive Disease in the First Trimester of Pregnancy: Risk Models and Analysis of Serum D-dimer Levels Combined with Plasma Pregnancy-Associated Protein A, Free β-Subunit of Human Chorionic Gonadotropin, and Fetal Nuchal Translucency.

Authors:  Yiming Chen; Wenwen Ning; Xuelian Chu; Yijie Chen; Linyuan Gu; Zhen Xie; Liyao Li; Caihe Wen; Xiaoying Wang
Journal:  Biomed Res Int       Date:  2022-03-30       Impact factor: 3.411

8.  Gestational weight gain and body composition of full-term newborns and infants: a cohort study.

Authors:  Sylvia R Nehab; Letícia D Villela; Fernanda V M Soares; Andrea D Abranches; Daniele M R Araújo; Leila M L da Silva; Yasmin N V Amaral; Saint Clair G Junior; Maria Dalva B B Meio; Maria Elisabeth Moreira
Journal:  BMC Pregnancy Childbirth       Date:  2020-08-20       Impact factor: 3.007

9.  Effect of baicalin on gestational hypertension-induced vascular endothelial cell damage.

Authors:  Yang Liu; Miao Xiong; Fangfang Zhou; Nana Shi; Yunbin Jia
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

Review 10.  Periodontal Conditions and Pathogens Associated with Pre-Eclampsia: A Scoping Review.

Authors:  Jocelyne Gare; Aida Kanoute; Nicolas Meda; Stephane Viennot; Denis Bourgeois; Florence Carrouel
Journal:  Int J Environ Res Public Health       Date:  2021-07-05       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.